Lenalidomide IH

Global calcium is one of the leading manufacturers and exporters of Lenalidomide CAS No. 191732-72-6, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, global calcium has stood the test of time since its inception in 1979.

As manufacturer of Lenalidomide we hereby state the following facts about the drug:

Lenalidomide is indicated for the:

Lenalidomide is used for specific adult patients with:

Multiple Myeloma in combination with dexamethasone. Also, for multiple myeloma maintenance therapy in patients who have had an autologous hematopoietic stem cell transplantation (auto-HSCT).

Myelodysplastic Syndromes with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Mantle Cell Lymphoma (MCL) has relapsed or progressed after two prior therapies, one of which included bortezomib.

Previously treated Follicular Lymphoma (FL), used in combination with a rituximab product.

Previously treated Marginal Zone Lymphoma (MZL), used in combination with combination with a rituximab product.

Mechanism of action

Lenalidomide exerts its effects by modulating the cereblon E3 ubiquitin ligase complex, leading to degradation of key transcription factors and enhancing immune-mediated tumor cell killing.

Global calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market.